Quality of life scores improved in brensocatib treatment groups but did not reach statistical significance. 6.1.2.3 Pharmacodynamic findings Further pharmacodynamic analysis evaluated brensocatib’s inhibitory effects on different NSPs ( Cipolla et al., 2023 ).
← all excerpts
Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: mechanisms, clinical trials, and therapeutic prospects.
1
—
—